An overview of resistance to chemotherapy in osteosarcoma and future perspectives
作者机构：Cirugia OncologicaInstituto Nacional de Cancerologia(INCAN)Ciudad de Mexico 14080Mexico Posgrado en Ciencias MedicasFacultad de Ciencias de la SaludUniversidad AnahuacCiudad de Mexico 52786Mexico Departamento de PatologiInstituto Nacional de Cancerologia(INCAN)Ciudad de México 14080Mexico Catedras de Consejo Nacional de Ciencia y Tecnologia(CONACYT)Instituto Nacional de CancerologiaCiudad de Mexico 14080Mexico
出 版 物：《Cancer Drug Resistance》 (癌症耐药（英文）)
年 卷 期：2022年第5卷第3期
页 面：762-793页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Osteosarcoma therapy resistance tyrosine kinase inhibitor tumoral extracellular microenvironment cell cycle
摘 要：Osteosarcoma(OS)is the most common type of bone *** the availability of multimodal treatment with surgery and chemotherapy,the clinical results remain *** main reason for the poor outcomes in patients with OS is the development of resistance to methotrexate,cisplatin,doxorubicin,and *** and cellular mechanisms associated with resistance to chemotherapy include DNA repair and cell-cycle alterations,enhanced drug efflux,increased detoxification,resistance to apoptosis,autophagy,tumor extracellular matrix,and *** versatility of cells to generate chemoresistance has motivated the use of anti-angiogenic therapy based on tyrosine kinase *** approach has shown that other therapies,along with standard chemotherapy,can improve responses to therapy in patients with ***,microRNAs may act as predictors of drug resistance in *** review provides insight into the molecular and cellular mechanisms involved in the development of resistance during the treatment of OS and discusses promising novel therapies(e.g.,afatinib and palbociclib)for overcoming resistance to chemotherapy in OS.
维普期刊数据库